This site provides access to current scientific information about ZYTIGA® (abiraterone acetate). Explore Johnson & Johnson’s portfolio of transformative medicines across oncology, immunology, neuroscience, and more, advancing patient care globally. ZYTIGA is a CYP17 inhibitor indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior. Medscape - Prostate cancer dosing for Zytiga (abiraterone), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Zytiga (abiraterone acetate) is a type of hormone therapy that is used along with prednisone to treat men with prostate cancer that has spread to other parts of the body (metastasized). Abiraterone acetate is marketed by Janssen Biotech (a subsidiary of Johnson & Johnson) under the brand name Zytiga, [49] and by Sun Pharmaceutical under the brand name Yonsa. Overview: Abiraterone (Zytiga) is used for certain types of prostate cancer. Common side effects include hot flashes, headache, diarrhea, and joint pain. Abiraterone interacts with several. ABIRATERONE (a bir A ter one) treats prostate cancer. It works by decreasing levels of the hormone testosterone in the body. This prevents prostate cancer cells from spreading or growing. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. COMMON BRAND NAME (S): Yonsa, ZYTIGA Zytiga (Abiraterone Acetate Tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources. Abiraterone is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.